文献速递艾滋病与性传播感染

过继性T细胞疗法作为HIV治愈策略的挑战与机遇

Challenges and Opportunities of Using Adoptive T-Cell Therapy as Part of an HIV Cure Strategy.
PubMed 文献 · J Infect Dis · 2021-01-01

本文综述了经抗逆转录病毒治疗控制病毒复制但HIV特异性T细胞应答受损的HIV感染者中,过继性T细胞疗法作为HIV治愈策略组成部分的挑战与机遇。文章讨论了目前正在临床测试的体外生成HIV特异性T细胞的多种策略,并探讨了输注T细胞如何融入HIV治愈策略。

要点

  • HIV感染者经ART控制病毒后HIV特异性T细胞应答常受损。
  • 成功的HIV治愈策略需要持久强效的T细胞免疫监视。
  • 体外生成HIV特异性T细胞并回输是正在临床测试的策略。

核心结论

  • 过继性T细胞疗法有望成为HIV治愈策略的一部分,但需先恢复HIV特异性T细胞活性。

研究设计与样本

  • 综述,总结目前正在临床测试的体外生成HIV特异性T细胞的策略。

主要发现

  • HIV特异性T细胞应答因缺乏CD4辅助、病毒逃逸、T细胞耗竭及抗原撤除而受损。

临床怎么用

  • 在启动HIV治愈策略前,需考虑如何最佳恢复HIV特异性T细胞活性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

HIV-infected individuals successfully controlling viral replication via antiretroviral therapy often have a compromised HIV-specific T-cell immune response due to the lack of CD4 T-cell help, viral escape, T-cell exhaustion, and reduction in numbers due to the withdrawal of cognate antigen. A successful HIV cure strategy will likely involve a durable and potent police force that can effectively recognize and eliminate remaining virus that may emerge decades after an individual undergoes an HIV cure regimen. T cells are ideally suited to serve in this role, but given the state of the HIV-specific T-cell response, it is unclear how to best restore HIV-specific T-cell activity prior initiation of a HIV cure strategy. Here, we review several strategies of generating HIV-specific T cells ex vivo that are currently being tested in the clinic and discuss how infused T cells can be part of an HIV cure strategy.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Zhou Y, Maldini CR, Jadlowsky J, et al. Challenges and Opportunities of Using Adoptive T-Cell Therapy as Part of an HIV Cure Strategy. J Infect Dis. 2021. PMID: 33586770. doi:10.1093/infdis/jiaa223

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。